Cargando…
P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Autores principales: | Caimi, Paolo F, Ai, Weiyun Z, Pablo Alderuccio, Juan, Ardeshna, Kirit M, Hamadani, Mehdi, Hess, Brian, Kahl, Brad S, Radford, John, Solh, Melhem, Stathis, Anastasios, Luigi Zinzani, Pier, Wang, Ying, Qin, Yajuan, Wang, Luqiang, Xu, Cindy, Carlo-Stella, Carmelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431093/ http://dx.doi.org/10.1097/01.HS9.0000971424.40251.1c |
Ejemplares similares
-
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
por: Alderuccio, Juan P., et al.
Publicado: (2022) -
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022) -
PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022) -
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell
lymphoma: a review of clinical data
por: Furqan, Fateeha, et al.
Publicado: (2022) -
P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
por: Spira, A., et al.
Publicado: (2022)